Brief Report: Real-World Eligibility for Clinical Trials in Patients With Extensive-Stage SCLC at a Tertiary Care Center

Introduction: The CASPIAN and IMpower133 trials revealed a significant survival benefit of chemotherapy plus immunotherapy in patients with extensive-stage SCLC. The current study characterizes the proportion of real-world patients who would have met eligibility for these trials and highlights facto...

詳細記述

書誌詳細

主要な著者:	Navdeep Dehar, M.B.B.S., MD, MBT, FRCPC, Mahbuba Meem, MD, Ishita Aggarwal, MD, MPH, Wilma Hopman, MA, Pierre-Olivier Gaudreau, MD, PhD, MPs, FRCPC, Andrew Robinson, MD, MSc, FRCPC, Andrea S. Fung, MD, PhD
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2024-07-01
シリーズ:	JTO Clinical and Research Reports
主題:	SCLC Real world Clinical trial eligibility IMpower133 CASPIAN
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2666364324000663
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!